Gilead Doubles Down on CAR-T


This opinion piece presents the opinions of the author. It does not necessarily reflect the views of BioSpace.

Fresh from its $12 billion acquisition of Kite Pharma, Gilead is stepping in to buy Cell Design Labs. This CAR-T company was particularly attractive for its technology around bi-specific antigen recognition and its "Throttle" technology, described as an "on-off switch" for engineered T cells. The focus here is on more specific, and safer, control of CAR-T therapy.  

Read on for other top deal news from December.  -KT

Here's a roundup of these stories and other top deals and partnerships from the past month.

Read More From Karl Thiel:
Did SAGE Therapeutics Just Break the CNS Curse?

Back to news